This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Through a series of exclusive interviews and a survey of industry insiders, Connect in Pharma names the top pharmaceutical and manufacturing-related trends of 2023
In Drug Channels Institute’s list of the top 15 pharmacies of 2022 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. To complement that broader ranking, we rummaged around our DreamHouse to update our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues in 2022.
Every April is National Minority Health Month , organized by the U.S. Department of Health and Human Services. This month is intended to highlight the focus on improving the health of racial and ethnic minorities by reducing health disparities and increasing equal access to care.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Andrea Galbiati, Stefania Bova, Raffaella Pacchiana, Chiara Borsari, Marco Persico, Aureliano Zana, Stefano Bruno, Massimo Donadelli, Caterina Fattorusso, Paola Conti, European Journal of Medicinal Chemistry, 2023 [link] Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a key glycolytic enzyme, plays a crucial role in the energy metabolism of cancer cells and has been proposed as a valuable target for the development of anticancer agents.
Annual Drug Patent Expirations for ZOSYN+IN+PLASTIC+CONTAINER Zosyn In Plastic Container is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers. There… The post New patent expiration for Wyeth Pharms drug ZOSYN IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Annual Drug Patent Expirations for ZOSYN+IN+PLASTIC+CONTAINER Zosyn In Plastic Container is a drug marketed by Wyeth Pharms and is included in one NDA. It is available from two suppliers. There… The post New patent expiration for Wyeth Pharms drug ZOSYN IN PLASTIC CONTAINER appeared first on DrugPatentWatch - Make Better Decisions.
Today’s guest post comes from Edward Hensley, Chief Commercial Officer at AssistRx. Edward discusses how a technology-first approach automates manual processes for therapy initiation. He argues that such an approach can increase patient adherence, speed access to therapy, and improve the healthcare providers’ workflow. To learn about AssistRx’s technology-first solutions, click here to schedule a meeting at Asembia’s Specialty Pharmacy Summit.
In November 2022, the American Journal of Industrial Medicine (AJIM) published a special issue focusing on work-related fatigue. The issue explores factors that may increase work-related fatigue and actions to reduce work-related injuries and illnesses. [1] This issue is a result of discussions and collaborations from the 2019 NIOSH Working Hours, Sleep and Fatigue Forum and also pulls from reports by the National Institute for Occupational Safety and Health (NIOSH) on long work hours and shift
By Larry K. Houck — Eric Idle, as a body collector, immortalized the phrase, “Bring out your dead,” in the 1975 comedy classic, Monty Python and the Holy Grail. The Drug Enforcement Administration (“DEA”) could voice a modern variation, “Bring out your meds,” as the agency and its law enforcement partners host local drop-off locations nationwide for safe disposal of unneeded medication on Saturday, April 22, 2023, from 10:00 a.m. to 2:00 p.m. local time.
Real-world data and evidence are increasingly being used in health care decisions and publications. However, there are challenges in identifying suitable data for external control arms, and researchers need to consider solutions to address issues like data quality, bias, and selection bias when using real-world evidence for comparative efficacy analyses.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Times remain tough for private biotech venture capital funding. Access to capital is more constrained than it’s been in years, and companies are starting to feel the pinch. Yet, despite the pain after a cycle of excess, perhaps this return towards more discipline should be embraced. As has already been widely reported , aggregate venture capital funding in the first quarter of 2023 is well off its peaks of 2020-2022.
As a critical part of their job, firefighters often climb aerial ladders up to 30 meters (or 98 feet) long and positioned at various angles. Aerial ladders are mechanically-operated, long, extendable ladders mounted on fire trucks and are used to reach high places for extinguishing fires and rescue operations. While climbing, firefighters typically wear heavy protective equipment and may also carry additional equipment related to fighting fires or rescuing occupants from burning buildings.
By Larry K. Houck — Drugs and substances classified within schedule I of the federal Controlled Substances Act (“CSA”) by definition have a high potential for abuse, no currently accepted medical use in treatment in the United States, and lack accepted safety for use under medical supervision. 21 U.S.C. § 812(b)(1). Last month bipartisan legislation, S. 689 and H. 1393 introduced in the Senate and the House, would facilitate removing barriers to research and compassionate use for schedule I co
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs… The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug addiction is prevalent and deadly. In the US in 2021, more than 46 million people aged 12 or older had addiction to at least one substance, yet only 6.3% received treatment, according to the National Institute on Drug Abuse (NIDA). A complex mix of gene variants and environmental factors lies behind the compulsion to repeatedly take a drug and increase the dose, despite knowing the dangers.
Artificial intelligence (AI) AI has seen quite a boom in the last couple of years, overcoming challenges such as limited and low-quality data. Researchers can avoid numerous delays by employing AI for drug discovery, often using computational approaches in combination with their own techniques, for a faster and smoother path to the clinic. 1 Getting to grips with what AI can do and how best to acquire and utilise its skills.
The development of new drugs and biological products has traditionally mandated animal testing, but the FDA Modernization Act 2.0 allows for alternative non-clinical testing, allowing reliable alternatives for drug discovery and biological product applications.
Annual Drug Patent Expirations for PRESTALIA Prestalia is a drug marketed by Adhera and is included in one NDA. There are two patents protecting this drug and one Paragraph IV… The post New patent expiration for Adhera drug PRESTALIA appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
On Thursday, April 20, from 1:30-3:00pm, John Claud of Hyman, Phelps & McNamara, P.C. will present a webinar entitled “ Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC.” John will provide participants with a greater understanding of new guidance implications, as well as recent guidance on delaying, denying, limiting, or refusing an inspection, and the DOJ’s revised Corporate Enforcement Policy, which altered the way the agency reviews corporate criminal prosecution
RENO, Nev.–(BUSINESS WIRE)–Crucial Data Solutions (CDS), a provider of innovative technologies to advance clinical research, announced today that industry veteran. The post Jim Bob Ward Appointed as Chief Strategy Officer at eClinical Provider Crucial Data Solutions appeared first on Crucial Data Solutions.
Although radiotherapy (also called radiation therapy ) is an important aspect of cancer treatment, it has limitations, including its potential for damaging healthy tissues, induction of radiotherapy resistance, requiring well-oxygenated tumors, and potentially increasing the risk for generating metastases. There remains an unmet need for ways to enhance radiotherapy.
Annual Drug Patent Expirations for EYSUVIS Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. It is available from one supplier. There are thirteen… The post New patent for Alcon Labs drug EYSUVIS appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Commonly used methods to handle the complexities of effect modification in indirect treatment comparisons (ITCs) often rely on the shared effect modifier (SEM) assumption, that is, that the effect modifiers impact a set of treatments in the evidence network in the same way. However, it has been argued that this assumption is limiting and often unreasonable to make.
An insightful piece from the Life Sciences Trainers & Educators Network (LTEN) focusing on Building the Right Learning Technology Architecture sparked a conversation at ACTO about determining the value that your learning technology stack delivers and the importance of defining that correctly. In the LTEN article, Rich Baron aptly stated, “It’s not about which technology is best.
Effective participant recruitment is crucial to a successful clinical trial, but recruiting eligible participants in sufficient numbers has long been a challenge. As trials become more complex, and calls for appropriate diversity in participant populations increase, the problem is intensifying. Smaller sites often have the most difficulty, and fewer resources for meeting the challenges.
Annual Drug Patent Expirations for PHENYLEPHRINE+HYDROCHLORIDE Phenylephrine Hydrochloride is a drug marketed by Akorn, Mankind Pharma, Paragon Bioteck, Accord Hlthcare, Amneal, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd,… The post New patent for HIKMA drug PHENYLEPHRINE HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.
Asthma is a condition that can impact anyone — and currently, it affects over 26.5 million people in the United States. In spite of available treatments, asthma is responsible for 1.3 million emergency room visits and over 3,500 deaths every year. Additionally, asthma’s impact is not evenly distributed; the condition impacts a disproportionate number of women, children, and minority populations, and has a direct correlation with an individual’s socioeconomic status.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content